What's in Genzyme, a Sanofi Company's pipeline?

Genzyme, a Sanofi Company has 51 drugs in our index: 14 marketed, 0 filed, 10 in Phase 3, 17 in Phase 2, 10 in Phase 1.

Which companies overlap with Genzyme, a Sanofi Company's portfolio?

Top competitors by shared drug class: Pfizer, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Hospices Civils de Lyon.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/genzyme-a-sanofi-company.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Genzyme, a Sanofi Company — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genzyme, a Sanofi Company pipeline: 14 marketed, 0 filed, 10 Phase 3, 17 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

14 marketed 0 filed 10 Phase 3 17 Phase 2 10 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Fitusiran (SAR439774)	Fitusiran (SAR439774)	marketed	RNA interference (RNAi) therapeutic; antithrombin silencer	Antithrombin (AT) mRNA	Hematology
Aldurazyme	Aldurazyme	marketed			Other
Caprelsa	Caprelsa	marketed		AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial	Oncology
Calcium-based phosphate binder	Calcium-based phosphate binder	marketed
ALGLUCOSIDASE ALFA (MYOZYME)	ALGLUCOSIDASE ALFA (MYOZYME)	marketed	Enzyme replacement therapy	Acid alpha-glucosidase (GAA)	Rare genetic disease / Metabolic disorder
doxercalciferol capsules, Hectorol®	doxercalciferol capsules, Hectorol®	marketed	Vitamin D analog	Vitamin D receptor (VDR)	Endocrinology / Nephrology
doxercalciferol capsules, Hectorol® capsules	doxercalciferol capsules, Hectorol® capsules	marketed	Vitamin D analog	Vitamin D receptor (VDR)	Endocrinology / Nephrology
Myozyme® (alglucosidase alfa)	Myozyme® (alglucosidase alfa)	marketed	Enzyme replacement therapy	Acid alpha-glucosidase (GAA); lysosomal glycogen	Rare genetic disease / Metabolic disorder
Colesevelam hydrochloride film-coated tablets	Colesevelam hydrochloride film-coated tablets	marketed
Myozyme	Myozyme	marketed			Rare Disease
Alemtuzumab (GZ402673)	Alemtuzumab (GZ402673)	marketed	Monoclonal antibody (CD52 antagonist)	CD52	Immunology / Hematology
Weight-Based Plerixafor	Weight-Based Plerixafor	marketed

Therapeutic area mix

Oncology · 13
Endocrinology / Nephrology · 2
Hematology · 2
Rare genetic disease / Metabolic disorder · 2
Nephrology · 2
Other · 2
Rare Genetic Disorder / Metabolic Disease · 1
Immunology / Hematology · 1
Cardiovascular, Endocrinology · 1
Rare Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 4 shared drug classes
Eli Lilly and Company · 3 shared drug classes
Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Hospices Civils de Lyon · 2 shared drug classes
ISU Abxis Co., Ltd. · 2 shared drug classes
Beijing InnoCare Pharma Tech Co., Ltd. · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Genzyme, a Sanofi Company:

Cite this brief

Drug Landscape (2026). Genzyme, a Sanofi Company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/genzyme-a-sanofi-company. Accessed 2026-05-16.